4-EA-NBOMe

4-EA-NBOMe
Legal status
Legal status	UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 1-(4-ethylphenyl)-N-[(2-methoxyphenyl)methyl]propan-2-amine;
JSmol)	Interactive image;
	SMILES CCC1=CC=C(C=C1)CC(C)NCC2=CC=CC=C2OC;
	InChI InChI=1S/C19H25NO/c1-4-16-9-11-17(12-10-16)13-15(2)20-14-18-7-5-6-8-19(18)21-3/h5-12,15,20H,4,13-14H2,1-3H3; Key:WWWBFWRUWWKJIJ-UHFFFAOYSA-N;

4-EA-NBOMe is a substituted amphetamine and 25-NB derivative which has been sold as a designer drug. It was first identified by a forensic laboratory in Germany in 2014,^[1] but while its analytical properties and metabolism have been studied,^[2]^[3]^[4] its pharmacology remains unknown.

References

^ "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015.
PMID 26606897
.

S2CID 206923339
.

PMID 29277574
.

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.
v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=4-EA-NBOMe&oldid=1187507004"

[1] "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015.

[pmid26606897-2] PMID 26606897
.

[pmid28762065-3] S2CID 206923339
.

[pmid29277574-4] PMID 29277574
.

[1]

[2]

[3]

[4]

See also

References